Identification of a human estrogen receptor α-derived antiestrogenic peptide that adopts a polyproline II conformation

Journal of Peptide Science

Volumn 15, Issue 7, 2009, Pages 455-464

  Kapitán, Josef ^a   Gallo, Dominique ^b   Goasdoué, Nicole ^c,d   Nicaise, Magali ^e   Desmadril, Michel ^e   Hecht, Lutz ^a   Leclerq, Guy ^b   Barron, Laurence D ^a   Jacquot, Yves ^c,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

^c Centre National de la Recherche Scientifique   (France)

^d ECOLE NORMALE SUPÉRIEURE   (France)

^e INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Antiestrogenic activity; CD spectroscopy; Estrogen receptor; Peptide; Polyproline II; ROA spectroscopy

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; POLYPEPTIDE; PROLINE;

ARTICLE; BREAST CANCER; CIRCULAR DICHROISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; RAMAN SPECTROMETRY; TEMPERATURE DEPENDENCE; TRANSCRIPTION REGULATION;

EID: 67849121678     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1136     Document Type: Article

References (82)

1. Ball LJ, Kühne R, Schneider-Mergener J, Oschkinat H. Recognition of proline-rich motifs by protein-protein interaction domains. Angew. Chem. Int. Ed. 2005; 44: 2852.
2. Kay BK, Williamson MP, Sudol M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domain. FASEB J. 2000; 14: 231.
3. Zarrinpar A, Bhattacharyy RP, Lim WA. The structure and function of proline recognition domains. Sci. STKE 2003; 179: RE8.
4. Dalgarno DC, Botfield MC, Rickles RJ. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers 1997; 43: 383.
5. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 1994; 76: 933.
6. Sudol M, Chen I, Bougeret C, Einbond A, Bork P. Characterization of a novel protein-binding module - the WW domain. FEBS Lett. 1995; 369: 67.
7. Sudol M. Structure and function of WW domain. Prog. Biophys. Mol. Biol. 1996; 65: 113.
8. Sudol M, Sliwa K, Russo T. Functions ofWWdomains in nucleus. FEBS Lett. 2001; 490: 190.
9. Zarrinpar A, LimWA. Converging on proline: the mechanism of WW domain peptide recognition. Nat. Struct. Biol. 2000; 7: 611.
10. Pornillos O, Alam SL, Rich RL, Myszka DG, Davis DR, Sundquist WI. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 2002; 21: 2397.
11. Ball LJ, Jarchau T, Oschkinat H, Walter U. EVH1 domains: structure, function and interactions. FEBS Lett. 2002; 513: 45.
12. Carl UD, Pollmann M, Orr E, Gertler FB, Chakraborty T, Wehland J. Aromatic and basic residues within EVH1 domain of VASP specify its interaction with proline-rich ligands. Curr. Biol. 1999; 9: 715-718.
13. Freund C, Dötsch V, Nishizawa K, Reinherz EL, Wagner G. The GYF domain is a novel structural fold that is involved in lymphoid signaling through proline-rich sequences. Nat. Struct. Biol. 1999; 6: 656.
14. Freund C, Kühne R, Yang H, Park S, Reinherz EL, Wagner G. Dynamic interaction of CD2 with the GYF and the SH3 domain of compartimentalized effector molecules. EMBO J. 2002; 21: 5985.
15. Freund C, Kühne R, Park S, Thiemke K, Reinherz EL, Wagner G. Structural investigations of a GYF domain covalently linked to a proline-rich peptide. J. Biomol. NMR 2003; 27: 143.
16. Saito K, Kigawa T, Koshiba S, Sato K,Matsuo Y, Sakamoto A, Takagi T, Shirouzu M, Yabuki T, Nunokawa E, Seki E, Matsuda T, Aoki M, Miyata Y, Hirakawa N, Inoue M, Terada T, Nagase T, Kikuno R, Nakayama M, Ohara O, Tanaka A, Yokoyama S. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKγ. Structure 2004; 12: 1719.
17. Weisbrich A, Honnappa S, Jaussi R, Okhrimenko O, Frey D, Jelesarov I, Akhmanov A, Steinmetz MO. Structure-function relationship of CAP-Gly domains. Nat. Struct. Biol. 2007; 14: 959.
18. Mahoney NM, Janmey PA, Almo SC. Structure of the profilin-polyL- proline complex involved in morphogenesis and cytoskeletal regulation. Nat. Struct. Biol. 1997; 4: 953.
19. Ostrander DB, Ernst EG, Lavoie TB, Gorman JA. Polyproline binding is an essential function of human profilin in yeast. Eur. J. Biochem. 1999; 262: 26.
20. Rabanal F, Ludevid MD, Pons M, Giralt E. CD of proline-rich polypeptides: application to the study of the repetitive domain of maize glutelin-2. Biopolymers 1993; 33: 1019.
21. Myllyharju J, Kivirikko KI. Identification of a novel proline-rich peptide-binding domain in prolyl 4-hydroxylase. EMBO J. 1999; 18: 306.
22. Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003; 22: 15.
23. Renfranz PJ, Beckerle M. Doing (F/L)PPPPs: EVH1 domains and the proline-rich partners in cell polarity and migration. Curr. Opin. Cell. Biol. 2002; 14: 88.
24. Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 2004; 14: 461.
25. Sundquist WI, Schubert HL, Kelly BN, Hill GC, Holton JM, Hill CP. Ubiquitin recognition by the human TSG101 protein. Mol. Cell. 2004; 13: 783.
26. VanDemark AP, Hofmann RM, Tsui C, Pickart CM, Wolberge C. Molecular insights into polyubiquitin chain assembly: crystal structure of the MmS2/Ubc13 heterodimer. Cell 2001; 105: 711.
27. Isley JL, Sudol M, Winder SJ. The WW domain: linking cell signaling to themembrane cytoskeleton. Cell. Signal. 2002; 14: 183.
28. Adzhubei AA, Sternberg MJE. Left-handed polyproline II helices commonly occur in globular proteins. J. Mol. Biol. 1993; 229: 472.
29. Bochicchio B, Tamburro AM. Polyproline II structure in proteins: identification by chiroptical spectroscopies, stability and functions. Chirality 2002; 14: 782.
30. Creamer TP, Campbell MN. Determinants of the polyproline II helix from modelling studies. Adv. Protein Chem. 2002; 62: 263.
31. Cubellis MV, Caillez F, Blundell TL, Lovell SC. Properties of polyproline II, a secondary structure element implicated in protein-protein interactions. Proteins 2005; 58: 880.
32. Ferreon JC, Hilser VJ. The effect of the polyproline II (PPII) conformation on the denatured state entropy. Protein Sci. 2003; 12: 447.
33. II) structural bias in the denatured states of proteins. Biochemistry 2004; 43: 9790.
34. Rath A, Davidson AR, Deber CM. The structure of unstructured regions in peptides and proteins: role of the polyproline II helix in protein folding and recognition. J. Pept. Sci. 2005; 80: 179.
35. Williamson MP. The structure and function of proline-rich regions in proteins. Biochem. J. 1994; 297: 249.
36. Chardin P, Camonis JH, Gale NW, Van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D. Human Sos 1: a guanine exchange factor for Ras that binds to Grb2. Science 1993; 260: 1338.
37. Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP, Garbay C. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J. 1999; 13: 31.
38. Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA. Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science 1998; 282: 2088.
39. Jacquot Y, Broutin I, Miclet E, Nicaise M, Lequin O, Goasdouè N, Joss C, Karoyan P, Desmadril M, Ducruix A, Lavielle S. High affinity Grb2-SH3 domain ligand incorporating Cβ-substituted prolines in a Sos-derived decapeptide. Bioorg. Med. Chem. 2007; 15: 1439.
40. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor a in breast cancer cells. Clin. Cancer Res. 2004; 10: 3621.
41. Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B, Chen S. PNRC: a proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (Steroidogenic Factor 1) and ERRα1 (Estrogen Related Receptor α-1). Mol. Endocrinol. 2000; 14: 986.
42. Zhou D, Chen S. PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif. Nucleic Acids Res. 2001; 29: 3939.
43. Zhou D, Chen B, Ye JJ, Chen S. A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction. Oncogene 2004; 23: 5394-5404.
44. Zhou D, Ye JJ, Li Y, Lui K, Chen S. The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC an estrogen receptor alpha. Nucleic Acids Res. 2006; 34: 5974.
45. Zhou D, Zhong S, Ye JJ, Quac KM, Johnson DL, Chen S. PNRC is a unique nuclear receptor coactivator that stimulates RNA polymerase III-dependent transcription. J. Mol. Signal. 2007; 2: 5.
46. Gallo D, Jacquemotte F, Cleeren A, Laïos I, Hadiy S, Rowlands MG, Caille O, Nonclerc D, Laurent G, Jacquot Y, Leclercq G. Calmodulinindependent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor α. Mol. Cell. Endocrinol. 2007; 268: 37.
47. Gallo D, Leclercq G, Jacquot Y. The N-terminal part of the ligandbinding domain of the human estrogen receptor a: a new target for estrogen disruptors. In Medicinal Chemistry Research Progress 2008; Nova Science Publishers, Inc (in press).
48. Jacquot Y, Gallo D, Leclercq G. Estrogen receptor alpha - Identification by a modelling approach of a potential polyproline II recognizing domain within the AF-2 region of the receptor that would play a role of prime importance in its mechanism of action. J. Steroid Biochem. Mol. Biol. 2007; 104: 1.
49. Gallo D, Jacquot Y, Cleeren A, Jacquemotte F, Laïos I, Laurent G, Leclercq G. Molecular basis of agonistic activity of ERα17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor α ligand binding domain. Lett. Drug Des. Discov. 2007; 4: 346.
50. Gallo D, Jacquot Y, Laurent G, Leclercq G. Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer. Mol. Cell. Endocrinol. 2008; 291: 20.
51. Gallo D, Haddad I, Duvillier H, Jacquemotte F, Laurent G, Jacquot Y, Vinh J, Leclercq G. Trophic effect in MCF-7 cells of ERα 17p, a peptide corresponding to a platform regulatory motif of the estrogen receptor α - Underlying mechanisms. J. Steroid Biochem. Mol. Biol. 2008; 109: 138.
52. Li L, Li Z, Howley PM, Sacks DB. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 2006; 281: 1978.
53. Miclet E, Jacquot Y, Goasdoué N, Lavielle S. Solution structural study of a proline-rich decapeptide. C. R. Chimie 2008; 11: 486.
54. Zhu F, Isaacs NW, Hecht L, Barron LD. Raman optical activity: a tool for protein structure analysis. Structure 2005; 13: 1409.
55. Borras M, Lacroix M, Legros N, Leclercq G. Estrogen receptor-negative/ progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. Cancer Lett. 1997; 120: 23.
56. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320: 134.
57. Pons M, Gagne D, Nicolas JC, Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 1990; 9: 450.
58. Wärnmark A, Treuter E, Gustafsson JAA, Hubbard RE, Brzozowski AM, Pike ACW. Interaction of transcriptionnal intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of the estrogen receptor α. J. Biol. Chem. 2002; 277: 21862.
59. Shi Z, Woody RW, Kallenbach NR. Is polyproline II a major conformation in unfolded proteins?. Adv. Protein Chem. 2002; 62: 163.
60. Kelly MA, Chellgren BW, Rucker AL, Troutman JM, Fried MG, Miller AF, Creamer TP. Host-guest study of left-handed polyproline II helix formation. Biochemistry 2001; 40: 14376.
61. 8 adopting a polyproline II conformation. J. Org. Chem. 1996; 61: 6775.
62. Helbecque N, Loucheux-Lefebvre MH. Critical chain length for polyproline-II structure formation in H-Gly-(Pro)n-OH. Int. J. Pept. Protein Res. 1982; 19: 94.
63. Tiffany ML, Krimm S. Circular dichroism of poly-L-proline in an unordered conformation. Biopolymers 1968; 6: 1767.
64. Torchia DA, Bovey FA. A nuclear magnetic resonance study of poly(L-proline) in aqueous and aqueous salt solutions. Macromolecules 1971; 4: 246.
65. Barron, LD. Molecular Light Scattering and Optical Activity, 2nd edn, Cambridge University Press: Cambridge; 2004.
66. Barron LD. Structure and behaviour of biomolecules from Raman optical activity. Curr. Opin. Struct. Biol. 2006; 16: 638.
67. McColl IH, Blanch EW, Hecht L, Kallenbach NR, Barron LD. Vibrational Raman optical activity characterization of poly(L-proline) II helix in alanine oligopeptides. J. Am. Chem. Soc. 2004; 26: 5076.
68. Kapitán J, Baumruk V, Bour P. Demonstration of the ring conformation in polyproline by the Raman optical activity. J. Am. Chem. Soc. 2006; 128: 2438.
69. Richardson JM, Makhatadze GI. Temperature dependence of the thermodynamics of helix-coil transition. J. Mol. Biol. 2004; 335: 1029.
70. Woody RW. Circular dichroism and conformation of unordered polypeplides. Adv. Biophys. Chem. 1992; 2: 37.
71. Pierrat B, Heery DM, Chambon P, Losson R. A highly conserved region in the hormone-binding domain of the human estrogen receptor functions as an efficient transactivation function in yeast. Gene 1994; 143: 193.
72. Zhu F, Kapitán J, Tranter GE, Pudney PDA, Isaacs NW, Hecht L, Barron LD. Residual structure in disordered peptides and unfolded proteins from multivariate analysis and ab initio simulation of Raman optical activity data. Proteins 2008; 70: 823.
73. Kapitán J, Baumruk V, Kopecky V, Bour P. Conformational flexibility of L-alanine zwitterion determines shapes of Raman and Raman Optical Activity spectral bands. J. Phys. Chem. A 2006; 110: 4689.
74. Creamer TP. Left-handed polyproline II helix formation is (very)locally driven. Proteins 1998; 33: 218.
75. Hinderaker MP, Raines R. An electronic effect on protein structure. Protein Sci. 2003; 12: 1188.
76. Krimm S, Tiffany ML. The circular dichroism spectrum and structure of unordered polypeptides and proteins. Isr J. Chem. 1974; 12: 189.
77. Huang J, Koide A, Nettle KW, Greene GL, Koide S. Conformation-specific affinity purification of proteins using engineered binding proteins: Application to the estrogen receptor. Protein Expr. Purif. 2006; 47: 348.
78. Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 1998; 284: 1141.
79. Koide A, Abbatiello S, Rothgery L, Koide S. Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor. Proc. Natl. Acad. Sci. USA 2002; 99: 1253.
80. Koide A, Koide S. Monobodies: Antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 2006; 352: 95.
81. Kong EH, Heldring N, Gustafsson JAA, Treuter E, Hubbard RE, Pike ACW. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. USA 2005; 102: 3593.
82. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. Peptide antagonists of the human estrogen receptor. Science 1999; 285: 744.